#Oxford vaccine

.London, UK
On February 11, WHO recommended use of the AstraZeneca COVID-19 vaccine for all, including those aged 65 or older. (Photo Credit: PTI)

  • The aim of new trial is to determine whether the vaccine is effective on people between the ages of 6 and 17
  • Around 300 volunteers will be enrolled and first inoculations are expected this month
  • Oxford/AstraZeneca coronavirus vaccine is a two-dose vaccine and it is cheaper and easier to distribute

.Genève, Switzerland
AstraZeneca vaccine is yet to get approval for emergency use by the WHO (Photo Credit: AP/PTI)

  • Strategic Advisory Group of Experts on Immunization (SAGE) made the recommendation
  • The doubt about the vaccine's efficacy was amplified due to lack of data
  • Experts have also suggested increasing the gap between the jabs to increase efficiency 

.Cape Town, South Africa
South Africa has aimed to administer nearly 40 million people (67% of the population) by the end of 2021. (Photo Credit: Representational Image/Pixabay)

  • Johnson & Johnson vaccine has been proven effective against the new variant, said MKhize
  • South Africa has ordered nine million doses of the J&J vaccines
  • The stock would be available in April, added the minister

.London, UK
The AstraZeneca COVID-19 vaccine has been developed in a joint effort by the company and Oxford University (Photo Credit: Twitter @AstraZeneca)

  • Research showed that the vaccine has a "similar efficacy" against other variants of the virus
  • The university said a reduced "duration of shedding and viral load" was observed 
  • The vaccine's efficiency against the South African variant is still unclear

.London, UK
AstraZeneca-Oxford announced that a new vaccine for the emerging COVID-19 variants is expected to be available by October (Photo Credit: Representational/Unsplash)

  • Deputy Chief Medical Officer of UK said the study will provide new insights about the vaccines
  • The study will test various combinations of different vaccines and their safety
  • Vaccines produced by AstraZeneca and Pfizer will tested in the study

.London, UK
UK PM Boris Johnson aims to vaccinate at least 15 million people vulnerable to the virus (Photo Credit: Representational Image/Unsplash)

  • A total of 10,021,471 people have received their initial jabs while 498,862 have received both doses
  • The British PM called the achivement a "milestone"
  • Johnson is currently reviewing the possibility of a third national lockdown in the country

.London, UK
The study's findings came amid much debate over the effectiveness of the AstraZeneca jab among the elderly. (Photo Credit: AP/PTI)

  • An Oxford  study says people vaccinated with a single dose of the vaccine were 67% less likely to test positive
  • Researchers found that a single dose was 76% effective in preventing virus symptoms after 22 days
  • Several countries have advised against administering the AstraZeneca jab to older people

.Paris, France
President Emmanuel Macron also questioned UK's decision of holding onto the second phase of vaccination. (Photo credit: Facebook/Emmanuel Macron)

  • The comments by Macron came hours prior to the European Medicines Agency's recommendation for the vaccine
  • The French President said there was 'very little information' available regarding the development of the vaccine
  • The expert decision by the French health authorities are expected to come out early next week

.Brussels, Belgium
AstraZeneca is working with Oxford to produce COVID-19 vaccines (Photo Credit: AFP)

  • The EU and AstraZeneca have an agreement of 400 million jabs 
  • After Moderna and Pfizer-BioNTech, this is the third COVID-19 vaccine to be approved by EU 
  • Earlier today, the EMA recommeded its use on people over the age of 18 

.Brussels, Belgium
AstraZeneca said that late-stage trials showed its coronavirus vaccine was up to 90% effective. (Photo Credit: AP/PTI)

  • The decision paves the way for a third vaccine to be approved in the EU, after the ones developed by Pfizer-BioNTech and Moderna
  • However, Germany has advised against its use among the over-65s due to a lack of data
  • The decision comes as AstraZeneca and the EU remain locked in a dispute over supply issues